In short
Clinical trials are studying ALLO-QUADCAR01-T in people with hard-to-treat B-cell cancers, including relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. These trials are mainly checking safety, tolerability, and early signs of how well the treatment works.
Key points
- ALLO-QUADCAR01-T is being studied in an authorised Phase 1/2 trial for people with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia. The study first checks safety, tolerability, and dose-related side effects. It then looks for early signs of benefit, including complete response rate. The trial plans to enroll 196 participants. The study is designed to help researchers find the recommended Phase 2 dose and learn whether ALLO-QUADCAR01-T may work in these hard-to-treat cancers.
Trial overview
The clinical trial titled QUADvance is studying ALLO-QUADCAR01-T in people with hard-to-treat B-cell cancers. The trial is an interventional study, which means researchers give the study treatment and then measure what happens.
The trial is authorised and is being run as a Phase 1/2 study. It is looking at both safety and early signs of benefit in people with relapsed or refractory disease.
Who the study is for
This study is for people with relapsed/refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia. Relapsed means the cancer came back after treatment, and refractory means the cancer did not respond well to treatment.
These are serious blood cancers that can be difficult to treat when earlier therapies have not worked well.
What researchers are measuring
The first part of the study, Phase Ia, is checking dose-limiting toxicity, which means side effects that are serious enough to limit the dose that can be given. This helps researchers learn whether different dose levels can be given safely.
In Phase Ib, the study measures the incidence, type, and severity of all adverse events, treatment-emergent adverse events, treatment-related adverse events, and serious adverse events. An adverse event is any medical problem seen during the study, whether or not it is caused by the treatment.
In Phase II, the main outcome is the complete response rate through and including the Week 13 assessment visit. Complete response rate means how many participants have no visible signs of cancer at that time point.
The brief study summary also says that Phase Ib is meant to confirm the recommended Phase 2 dose, which is the dose chosen for later studies after early safety testing.
Trial phase and study plan
The study has three main parts: Phase Ia, Phase Ib, and Phase II. Phase Ia focuses on safety and tolerability at different dose levels. Tolerability means how well people can handle the treatment side effects.
Phase Ib continues the safety work and helps confirm the dose for the next stage of research. Phase II then looks more closely at clinical efficacy, which means whether the treatment may help control the cancer.
Study size and status
The planned enrollment is 196 people. This number gives researchers enough participants to gather useful safety data and early effectiveness results.
The trial status is listed as authorised. That means the study has approval to proceed.
What this means for patients
For patients with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia, this trial is part of early research into a new treatment option. The main goal is not only to see whether ALLO-QUADCAR01-T can be given safely, but also whether it shows early signs of helping the cancer.
Because this is an early phase study, the results will mainly help researchers understand safety, dose selection, and early response rather than provide final proof of benefit.